Andy Weymann
Chief Executive Officer at Gelmetix Ltd.
Andy Weymann active positions
Companies | Position | Start | End |
---|---|---|---|
VirtaMed AG
VirtaMed AG Personnel ServicesCommercial Services VirtaMed AG develops and produces surgical simulators for medical training. The company was founded by G?bor Sz?kely, Stefan Tuchschmid, Raimundo Sierra and Daniel Bachofen on 2nd October 2007 and is headquartered in Schlieren, Switzerland. | Director/Board Member | 31/05/2021 | - |
Gelmetix Ltd.
Gelmetix Ltd. Miscellaneous Commercial ServicesCommercial Services Gelmetix Ltd. offers a non-surgical procedure for the treatment of chronic lower back pain caused by degenerative disc disease. The firm develops a hydrogel to relieve back pain by enabling cells in the spinal disc to get back to normal functioning, which can be injected into the disc by a healthcare professional and replaces the need for invasive back surgery. The company was founded by Tony Freemont and Brian Saunders in 2012 and is headquartered in Cheshire, the United Kingdom. | Director/Board Member | - | - |
Chief Executive Officer | - | - | |
Speratum Biopharma, Inc.
Speratum Biopharma, Inc. BiotechnologyHealth Technology Speratum Biopharma, Inc. is a pre-clinical stage biotechnology company based in Dover, DE. Speratum is focused on the research and development of targeted molecular therapeutics for the treatment of cancer. The company's primary focus is developing a multi-component therapeutic against multiple cancer types that includes a proprietary RNA interference (RNAi)-inducing mimic of mir-198, a naturally occurring microRNA involved in the pathogenesis of several solid cancers, combined with a novel biocompatible material suitable for systemic and targeted delivery of nucleic acids. Speratum's platforms for drug delivery and oligonucleotide administration have broad application potential, and have been out-licensed for multiple therapeutic and research modalities. The company was founded by Christian Marín-Müller, who has been the CEO since incorporation. | Director/Board Member | - | - |
Career history of Andy Weymann
Training of Andy Weymann
University of Zurich | Graduate Degree |
University of Rochester Simon Business School | Masters Business Admin |
Statistics
International
Switzerland | 3 |
United States | 3 |
United Kingdom | 2 |
Operational
Director/Board Member | 3 |
Graduate Degree | 1 |
Masters Business Admin | 1 |
Sectoral
Commercial Services | 3 |
Consumer Services | 3 |
Health Technology | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Private companies | 3 |
---|---|
VirtaMed AG
VirtaMed AG Personnel ServicesCommercial Services VirtaMed AG develops and produces surgical simulators for medical training. The company was founded by G?bor Sz?kely, Stefan Tuchschmid, Raimundo Sierra and Daniel Bachofen on 2nd October 2007 and is headquartered in Schlieren, Switzerland. | Commercial Services |
Gelmetix Ltd.
Gelmetix Ltd. Miscellaneous Commercial ServicesCommercial Services Gelmetix Ltd. offers a non-surgical procedure for the treatment of chronic lower back pain caused by degenerative disc disease. The firm develops a hydrogel to relieve back pain by enabling cells in the spinal disc to get back to normal functioning, which can be injected into the disc by a healthcare professional and replaces the need for invasive back surgery. The company was founded by Tony Freemont and Brian Saunders in 2012 and is headquartered in Cheshire, the United Kingdom. | Commercial Services |
Speratum Biopharma, Inc.
Speratum Biopharma, Inc. BiotechnologyHealth Technology Speratum Biopharma, Inc. is a pre-clinical stage biotechnology company based in Dover, DE. Speratum is focused on the research and development of targeted molecular therapeutics for the treatment of cancer. The company's primary focus is developing a multi-component therapeutic against multiple cancer types that includes a proprietary RNA interference (RNAi)-inducing mimic of mir-198, a naturally occurring microRNA involved in the pathogenesis of several solid cancers, combined with a novel biocompatible material suitable for systemic and targeted delivery of nucleic acids. Speratum's platforms for drug delivery and oligonucleotide administration have broad application potential, and have been out-licensed for multiple therapeutic and research modalities. The company was founded by Christian Marín-Müller, who has been the CEO since incorporation. | Health Technology |
- Stock Market
- Insiders
- Andy Weymann
- Experience